PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • ID: 4206926
  • Report
  • Region: Global
  • 465 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AB Science
  • Biocad
  • Daiichi-Sankyo
  • Immunomedics
  • Merrimack
  • Sanofi
  • MORE
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

Summary

Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: Angiogenesis and EGFR inhibitors.

It is estimated that the value of the Colorectal Cancer (CRC) market in the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and China in 2015 was USD 8.15Billion. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. Just under half of these sales, USD 3.72Billion (46%), were generated in the US, with the 5EU representing the next largest region by sales, estimated at USD 2.71Billion (33%). Japan and China contributed the smallest proportion of sales to the global CRC market, with 2015 sales of USD 980Million (12%) and USD 735Million (9%), respectively.

By 2025, the end of the forecast period, projects CRC sales to rise to $10.97billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 3.0%. In particular, the author expects the Chinese CRC market to experience the highest growth, increasing to $1.25billion (11% total market share) by 2025, at a CAGR of 5.5%.

Major drivers of the growth of the CRC market over the forecast period include -
- Aging populations and rising incident cases of CRC across most markets (except the US) covered in this report is responsible for the forecasted market size growth. Overall, across the 8MM, the incidence of CRC is expected to increase by an Annual Growth Rate (AGR) of 2.2% from 2015-2025.
- The launch and uptake of premium-priced therapies will drive the growth in the CRC market.
- It is expected that the branded drugs to facilitate the gradual increase in the number of patients receiving branded therapy across different lines of metastatic therapy, thus increasing the patient pool of these segments and the overall CRC market size.

The report “PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025” provides an overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

It also provides the following:
- Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.
- Provides strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned this report: AB Science, Amgen, Array BioPharma, AstraZeneca, Bayer, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, BTG International, Daiichi-Sankyo, Cleveland Biolabs, Eli Lilly, GlaxoSmithKline, Gradalis, Hutchinson Medi Pharma, Immunomedics, Immunovative Therapies, Jiangsu Hengrui, Merck KGaA, Merck & Co., Merrimack, Mologen, Novartis, PsiOxus therapeutics, Roche/Genentech, Sanofi, Sorrento, Sirtex, Sumitomo Dainippon Pharma, Suzhou Zelgen, Symphogen, Taiho Pharmaceuticals, Takeda, Tracon Pharmaceuticals.

Scope

- Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global CRC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global CRC therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science
  • Biocad
  • Daiichi-Sankyo
  • Immunomedics
  • Merrimack
  • Sanofi
  • MORE
1 Table of Contents
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/ Targets of interest
3.2 Clinical Staging
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 8MM Incidence Trends
4.3.2 8MM, Trends in Five-Year Relative Survival
4.4 Forecast Methodology
4.4.1 Sources Used Tables
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for CRC (2015-2025)
4.5.1 Diagnosed Incident Cases of CRC
4.5.2 Age-Specific Diagnosed Incident Cases of CRC
4.5.3 Sex-Specific Diagnosed Incident Cases of CRC
4.5.4 Age-Standardized Diagnosed Incidence of CRC
4.5.5 Diagnosed Incident Cases of CRC by Stage at Diagnosis
4.5.6 Type of Genetic Mutation among Diagnosed Incident Cases of CRC
4.5.7 Five-Year Diagnosed Prevalent Cases of CRC
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Screening and Diagnosis
5.1.2 Treatment Guidelines and Leading Prescribed Drugs
5.1.3 Clinical Practice
5.2 US
5.2.1 Screening and Diagnosis
5.2.2 Clinical Practice
5.3 France
5.3.1 Screening and Diagnosis
5.3.2 Clinical Practice
5.4 Germany
5.4.1 Screening and Diagnosis
5.4.2 Clinical Practice
5.5 Italy
5.5.1 Screening and Diagnosis
5.5.2 Clinical Practice
5.6 Spain
5.6.1 Screening and Diagnosis
5.6.2 Clinical Practice
5.7 UK
5.7.1 Screening and Diagnosis
5.7.2 Clinical Practice
5.8 Japan
5.8.1 Screening and Diagnosis
5.8.2 Clinical Practice
5.9 China
5.9.1 Screening and Diagnosis
5.9.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Anti-angiogenesis drugs
6.2.1 Avastin (Bevacizumab)
6.2.2 Zaltrap (Ziv-Aflibercept)
6.2.3 Cyramza (Ramucirumab)
6.3 EGFR Targeted-therapies
6.3.1 Erbitux (Cetuximab)
6.3.2 Vectibix (Panitumumab)
6.4 Kinase Inhibitors
6.4.1 Stivarga (Regorafenib)
6.5 Chemotherapy
6.5.1 Lonsurf (Trifluridine + Tipiracil)
6.5.2 TS-1 (Tegafur + Gimeracil + Oteracil)
7 Unmet Need and Opportunity
7.1 Overview
7.2 Understanding and Overcoming Mechanisms of Resistance to Angionesis and EGFR Inhibitors
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Targeted Treatments for BRAF Mutation-Positive Patients
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Extending the Use of Immunotherapies to the MSS Population
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Identification of Positive Predictive Biomarkers
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
7.7 Additional and More Effective Later-Line Therapies for Chemotherapy-Resistant Patients
7.7.1 Unmet Need
7.7.2 Gap Analysis
7.7.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.3 Immunotherapies
8.3.1 Lefitolimod (MGN-1703)
8.3.2 Keytruda (pembrolizumab)
8.3.3 Tecentriq (atezolizumab)
8.4 Molecular-Targeted Agents
8.4.1 Encorafenib (LGX-818) + Binimetinib (MEK-162)
8.4.2 Napabucasin (BBI-608)
8.4.3 Vargatef (Nintedanib)
8.4.4 Masitinib (AB-1010)
8.4.5 Fruquintinib (HMPL-013)
8.4.6 Famitinib (SHR-1020)
8.4.7 Donafenib (CM-4307)
8.5 Promising Approaches in Early Stage Development
8.5.1 Strategies to Overcome VEGF-Resistance
8.5.2 Strategies for BRAF Mutation-Positive Disease
8.5.3 Strategies for RAS-Mutation Positive Disease
8.5.4 Strategies to Overcome EGFR-Acquired Resistance
8.5.5 Immune Checkpoint Inhibitors Combinations
8.5.6 Other Strategies
8.5.7 Liver Directed Therapies
8.6 Biosimilars
8.6.1 Bevacizumab Biosimilars
8.6.2 Cetuximab Biosimilars
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Amgen
9.3.2 Bayer
9.3.3 Eli Lilly and Company
9.3.4 Merck KGaA
9.3.5 Merck & Co.
9.3.6 Roche/Genentech
9.3.7 Taiho Pharmaceutical
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 United States
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5 EU
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 China
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed CRC Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Drug Assumptions
11.4.7 Generic Erosion
11.4.8 Pricing of Pipeline Agents
11.5 Primary Research - KOLs Interviewed for this Report
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Analyst
11.7.2 Reviewers
11.7.3 Therapy Area Director
11.7.4 Epidemiologist
11.7.5 Reviewers
11.7.6 Global Head of Healthcare
11.8 About
11.9 Disclaimer

List of Tables
Table 1: Stage Definitions for Colorectal Cancer
Table 2: Symptoms of CRC
Table 3: Prognosis for Colon and Rectal Cancer
Table 4: Risk Factors and Comorbidities For CRC
Table 5: 8MM, Five-Year Relative Survival (%)
Table 6: 8MM, Sources Used to Forecast the Diagnosed Incidence of CRC
Table 7: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC
Table 8: 8MM, Sources of CRC Cancer Stage at Diagnosis
Table 9: 8MM, Sources of Genetic Mutations
Table 10: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025
Table 11: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Row (%), 2015
Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages =18 Years, Row (%), 2015
Table 13: 8MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages =18 Years, Row (%), 2015
Table 14: 8MM, Diagnosed Incident Cases of CRC by Type of Genetic Mutation (N), Both Sexes, Ages =18 Years, 2015
Table 15: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025
Table 16: Treatment Guidelines for CRC
Table 17: Most Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage Colon and Rectal Cancer in the 8MM, 2016
Table 18: Most Prescribed Targeted Therapies for mCRC, by Segment in the 8MM, 2016
Table 19: Country Profile - US
Table 20: Country Profile - France
Table 21: Country Profile - Germany
Table 22: Country Profile - Italy
Table 23: Country Profile - Spain
Table 24: Country Profile - UK
Table 25: Country Profile - Japan
Table 26: Country Profile - China
Table 27: Leading Treatments for CRC, 2016
Table 28: Product Profile - Avastin
Table 29: Summary of the Results from the AVF2107 Trial of Avastin Plus IFL
Table 30: Summary of the Results from the CALGB 80405 and FIRE-3 Trials of Avastin/Erbitux plus Chemotherapy
Table 31: Summary of the Results of the ML18147 Study
Table 32: Summary of the Results from the E3200 Trial of Avastin Plus FOLFOX
Table 33: Summary of AEs from the AVF21070 trial of Avastin
Table 34: Avastin SWOT Analysis, 2016
Table 35: Product Profile - Zaltrap
Table 36: Summary of the Results from the VELOUR Study
Table 37: Summary of Frequent Grade 3 and 4 AEs from the VELOUR trial of Zaltrap
Table 38: Zaltrap SWOT Analysis, 2016
Table 39: Product Profile - Cyramza
Table 40: Summary of the Phase III RAISE Trial of Cyramza
Table 41: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Cyramza
Table 42: Cyramza SWOT Analysis, 2016
Table 43: Product Profile - Erbitux
Table 44: Summary of the Result of the CRYSTAL Study
Table 45: Summary of the Results of the CRYSTAL Study - BRAF Mutation
Table 46: Retrospective Analysis of CRYSTAL and FIRE-3 Studies of Erbitux
Table 47: Summary of Frequent AEs from the CRYSTAL Trial of Erbitux
Table 48: Erbitux SWOT Analysis, 2016
Table 49: Product Profile - Vectibix
Table 50: Summary of the Results from the PRIME Trial of Vectibix
Table 51: Summary of the Results from the PEAK Study of Vectibix
Table 52: Summary of the Results from the Phase III Study of Vectibix as Monotherapy
Table 53: Summary of the Results from the ASPECCT Study of Vectibix
Table 54: Incidence of Grade 3-4 AEs of the PRIME Trial of Vectibix
Table 55: Vectibix SWOT Analysis, 2016
Table 56: Product Profile - Stivarga
Table 57: Summary of the Results from the CORRECT Study of Stivarga
Table 58: Summary of Frequent Grade 3 and 4 AEs from the CORRECT Trial of Stivarga
Table 59: Stivarga SWOT Analysis, 2016
Table 60: Product Profile - Lonsurf
Table 61: Summary of the Phase III RECOURSE Trial of Lonsurf
Table 62: Summary of the AEs in the Phase III Trial of Lonsurf
Table 63: Lonsurf SWOT Analysis, 2016
Table 64: Product Profile - TS-1
Table 65: Summary of a Phase III trial of TS-1
Table 66 Summary of Most Common AEs in a Phase III Trial of TS-1
Table 67: TS-1 SWOT Analysis, 2016
Table 68: Unmet Needs and Opportunities in CRC
Table 69: Product Profile - Lefitolimod
Table 70: Summary of the IMPACT Trial of Lefitolimod
Table 71: Summary of the Most Common AEs Reported in the IMPACT Trial of Lefitolimod
Table 72: Lefitolimod SWOT Analysis, 2016
Table 73: Product Profile - Keytruda
Table 74 Summary of the Results of the Phase II Trial of Keytruda
Table 75: Summary of Frequent AEs in the Phase II Trial of Keytruda
Table 76: Keytruda SWOT analysis, 2016
Table 77: Product Profile - Tecentriq
Table 78: Summary of the Phase Ib Trial of Tecentriq
Table 79: Summary of Frequent AEs in the Phase Ib Trial of Tecentriq
Table 80: Tecentriq SWOT analysis, 2016
Table 81: Product Profile - Encorafenib +Binimetinib
Table 82: Summary of the Results from the Phase II Trial of Encorafenib
Table 83: Summary of Frequent AEs in the Phase II Trial of Encorafenib
Table 84: Encorafenib + binimetinib - SWOT Table, 2016
Table 85: Product Profile - Napabucasin
Table 86: Summary of the Result from the Phase Ib Trial of Napabucasin
Table 87: Summary of the Result from the Phase II Trial Investigating Napabucasin + Vectibix
Table 88: Napabucasin, SWOT Analysis, 2016
Table 89: Product Profile - Vargatef
Table 90: Summary of the Result of the Phase III LUME Colon-1 Trial of Vargatef
Table 91: Vargatef SWOT Analysis, 2016
Table 92: Product Profile - Masitinib
Table 93: Summary of the Results of the Phase II Trial of Masitinib
Table 94: Masitinib SWOT Analysis, 2016
Table 95: Product Profile - Fruquintinib
Table 96: Summary of the Results of the Phase II Trial of Fruquintinib
Table 97: Summary of Frequent AEs in the Phase II trial of Fruquintinib
Table 98: Fruquintinib SWOT Analysis, 2016
Table 99: Product Profile - Famitinib
Table 100: Summary of the Results of the Phase II Trial of Famitinib
Table 101: Summary of Frequent AEs in a Phase II trial of Famitinib
Table 102: Famitinib SWOT Analysis, 2016
Table 103: Product Profile - Donafenib
Table 104: Donafenib SWOT Analysis, 2016
Table 105: Promising strategies to overcome VEGF resistance
Table 106: Early-stage Strategies for BRAF Mutation-Positive CRC
Table 107: Early-stage Strategies for KRAS Mutation-Positive CRC
Table 108: Early-Stage Strategies for EGFR Acquired Resistance
Table 109: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC
Table 110: CAR-T Cell Therapies Under Development
Table 111: Vaccines in Development in CRC
Table 112: Radioembolization Tecnhiquese Evaluated for the Treatment of Colorectal Cancer Liver Metastasis
Table 113: List of Bevacizumab Biosimilars in Phase III Development
Table 114: Key Companies in the CRC Market in the 8MM, 2015-2025
Table 115: Amgen’s CRC Portfolio Assessment, 2016
Table 116: Bayer’s CRC Portfolio Assessment, 2016
Table 117: Eli Lilly’s CRC Portfolio Assessment, 2016
Table 118: Merck KGaA’s CRC Portfolio Assessment, 2016
Table 119: Merck & Co.’s CRC Portfolio Assessment, 2016
Table 120: Roche’s CRC Portfolio Assessment, 2016
Table 121: Taiho’s CRC Portfolio Assessment, 2016
Table 122: CRC Market Drivers and Barriers, 2016
Table 123: Key Events Impacting Sales for CRC in the US, 2015-2025
Table 124: US CRC Market Drivers and Barriers, 2016
Table 125: Key Events Impacting Sales for CRC in the 5EU, 2015-2025
Table 126: 5EU CRC Market Drivers and Barriers, 2016
Table 127: Key Events Impacting Sales for CRC in Japan, 2015-2025
Table 128: Japan CRC Market - Drivers and Barriers, 2016
Table 129: Key Events Impacting Sales for CRC in China, 2015-2025
Table 130: China CRC Market - Drivers and Barriers, 2016
Table 131: Key Historical and Projected Launch Dates for Colorectal Cancer
Table 132: Key Historical and Projected Patent Expiry Dates for Colorectal Cancer
Table 133 Average Body Weight and Surface Area Across the 8MM
Table 134: Treatment Duration in Colorectal Cancer
Table 135: Average Cost of Therapy of Avastin in the 8MM
Table 136: Average Cost per Cycle of Chemotherapy Regimens in the 8MM
Table 137: Average Cost of Therapy of Cyramza in the 8MM (excluding urban China)
Table 138: Average Cost of Therapy of Erbitux in the 8MM
Table 139: Average Cost of Therapy of Lonsurf in the 8MM
Table 140: Average Cost of Therapy of Stivarga in the 8MM
Table 141: Average Cost of Therapy of Vectibix in the 8MM
Table 142: Average Cost of Therapy of Zaltrap in the US and 5EU
Table 143: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Men, Ages =15 Years, 1998-2007
Figure 2: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Women, Ages =15 Years, 1998-2007
Figure 3: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025
Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Ages =18 Years, 2015
Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages =18 Years, 2015
Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages =18 Years, by Sex, 2015.
Figure 7: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages =18 Years, 2015-2025
Figure 8: Treatment Flowchart for Regional or Locoregional CRC
Figure 9: Treatment Flowchart for mCRC
Figure 10: The Zurich Treatment Algorithm
Figure 11: Avastin’s Development in CRC
Figure 12: Cyramza’s Development in CRC
Figure 13: Erbitux’s Development in CRC
Figure 14: Vectibix Development in CRC
Figure 15: Stivarga’s Development in CRC
Figure 16: Lonsurf’s Development in CRC
Figure 17: TS-1 Development in CRC
Figure 18: CRC - Phase III Pipeline, 2016
Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2015-2025
Figure 20: Lefitolimod’s Clinical Development in CRC
Figure 21: Clinical and Commercial Positioning of Lefitolimod
Figure 22: Keytruda’s Clinical Development in CRC
Figure 23: Clinical and Commercial Positioning of Keytruda
Figure 24: Tecentriq’s Clinical Development in CRC
Figure 25: Clinical and Commercial Positioning of Tecentriq
Figure 26: Encorafenib’s Clinical Development in CRC
Figure 27: Potential Clinical and Commercial Positioning for Encorafenib + BInimetinib
Figure 28: Napabucasin’s Clinical Development in CRC
Figure 29: Clinical and Commercial Positioning of Napabucasin
Figure 30: Vargatef’s Clinical Development in CRC
Figure 31: Clinical and Commercial Positioning of Vargatef
Figure 32:Masitinib’s Clinical Development in CRC
Figure 33: Clinical and Commercial Positioning of Masitinib
Figure 34: Fruquintinib’s Clinical Development in CRC
Figure 35: Clinical and Commercial Positioning of Fruquintinib
Figure 36: Famitinib’s Clinical Development in CRC
Figure 37: Clinical and Commercial Positioning of Famitinib
Figure 38: Donafenib’s Clinical Development in CRC
Figure 39: Clinical and Commercial Positioning of Donafenib
Figure 40: Clinical Development of Bevacizumab Biosimilars
Figure 41: Global Sales of Branded Products for CRC by Company, 2015-2025
Figure 42: Company Portfolio Gap Analysis in CRC, 2015-2025
Figure 43: Amgen SWOT Analysis in CRC, 2016
Figure 44: Bayer SWOT Analysis in CRC, 2016
Figure 45: Eli Lilly SWOT Analysis in CRC, 2016
Figure 46: Merck KGaA SWOT Analysis in CRC, 2016
Figure 47: Merck & Co. SWOT Analysis in CRC, 2016
Figure 48: Roche SWOT Analysis in CRC, 2016
Figure 49: Taiho SWOT Analysis in CRC, 2016
Figure 50: Global Sales for CRC by Region, 2015-2025
Figure 51: Global Sales for CRC by Drug Class, 2015-2025
Figure 52: Sales for CRC in the US, by Drug Class, 2015-2025
Figure 53: Sales for CRC in the 5EU, by Drug Class, 2015-2025
Figure 54: Sales for CRC in Japan, by Drug Class, 2015-2025
Figure 55: Sales for CRC in China by Drug Class, 2015-2025
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AB Science
  • Amgen
  • Array BioPharma
  • AstraZeneca
  • Bayer
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG International
  • Daiichi-Sankyo
  • Cleveland Biolabs
  • Eli Lilly
  • GlaxoSmithKline
  • Gradalis
  • Hutchinson Medi Pharma
  • Immunomedics
  • Immunovative Therapies
  • Jiangsu Hengrui
  • Merck KGaA
  • Merck & Co.
  • Merrimack
  • Mologen
  • Novartis
  • PsiOxus therapeutics
  • Roche/Genentech
  • Sanofi
  • Sorrento
  • Sirtex
  • Sumitomo Dainippon Pharma
  • Suzhou Zelgen
  • Symphogen
  • Taiho Pharmaceuticals
  • Takeda
  • Tracon Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll